Effective treatment options for diseases such as Alzheimer's, Parkinson's, and cataracts are needed. This new group of compounds have the potential to treat disorders caused by oxidative stress by functioning as antioxidants and metal chelators.

 Numerous disorders, including Alzheimer’s, Parkinson’s and cataracts are the result of cellular damage due to oxidative stress caused by an imbalance in the processes of reactive oxygen species (ROS) production and ROS removal.  Research has shown that antioxidants and metal chelators can reduce the generation of ROS either alone or in combination, and are therefore considered to be effective treatments for these and other ROS dependent disorders.  Researchers at the University of Nebraska Medical Center in Omaha, have developed a group of unique compounds that possess multifunctional antioxidant and chelation activity in both cellular and small animal models.  As the incidence of disorders such Alzheimer’s, Parkinson’s, and cataract continues to increase, these compounds have the potential to become the treatment of choice in disease management.

Early Stage

 Application Filed

(TID - 114)

 UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.